Online citations, reference lists, and bibliographies.
← Back to Search

Lipid Drug Conjugate Nanoparticle As A Potential Nanocarrier For The Oral Delivery Of Pemetrexed Diacid: Formulation Design, Characterization, Ex Vivo, And In Vivo Assessment.

Kriti Soni, A. Mujtaba, K. Kohli
Published 2017 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The present work was to develop lipid drug conjugated (LDC) nanoparticles for the potential oral delivery of pemetrexed diacid (PTX) and evaluation of its in vitro, ex vivo and in vivo potentials. The LDC was prepared by salt formation of PTX with stearic acid and followed by cold homogenization technique to produce the LDC nanoparticles. FTIR analysis of LDC proved the presence of amide bond in LDC powder indicating the conjugation between drug and lipid. LDC nanoparticles was found to have particle size 121.9±1.85nm and zeta potential -51.6mV±1.23 and entrapment efficiency 81.0±0.89%. TEM images revealed spherical morphology and were in corroboration with particle size measurements. Ex vivo gut permeation studies revealed a very good enhancement in permeation of drug present in the LDC as compared to plain drug solution and were confirmed by CLSM. MTT assay conformed significant% toxicity at the end of 24h and 48h. Furthermore, the AUC0-24 of PTX from the optimized LDC nanoparticels was found to be 4.22 folds higher than that from PTX suspension on oral administration. Thus, LDC has high potential for the oral delivery of PTX in cancer therapy and future prospects for the industrial purpose.
This paper references
10.1016/S0939-6411(02)00130-3
Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters.
M. Schubert (2003)
10.1155/2014/984756
Solid-Nanoemulsion Preconcentrate for Oral Delivery of Paclitaxel: Formulation Design, Biodistribution, and γ Scintigraphy Imaging
J. Ahmad (2014)
10.1634/theoncologist.2009-0092
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
M. Cohen (2009)
Solid lipid nanoparticles (SLN)--effects of lipid composition on in vitro degradation and in vivo toxicity.
H. Weyhers (2006)
10.1038/ng.608
Common SNPs explain a large proportion of the heritability for human height
J. Yang (2010)
10.1016/j.ijpharm.2014.11.001
Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment.
Y. R. Neupane (2014)
10.1016/J.CLINTHERA.2005.09.010
Pemetrexed: a multitargeted antifolate.
K. D. Rollins (2005)
10.5772/2889
Recent Advances in Novel Drug Carrier Systems
A. Sezer (2012)
10.1208/s12249-011-9665-3
Preparation, Characterization, Pharmacokinetics and Tissue Distribution of Solid Lipid Nanoparticles Loaded with Tetrandrine
S. Li (2011)
10.1002/jps.22292
Optimization and formulation design of gels of Diclofenac and Curcumin for transdermal drug delivery by Box-Behnken statistical design.
Hema Chaudhary (2011)
10.1634/THEONCOLOGIST.6-4-363
Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
A. Hanauske (2001)
10.7326/0003-4819-108-3-502_1
Drug facts and comparisons
Erwin K. Kastrup (1977)
10.2307/1270613
Response Surface Methodology: Process and Product in Optimization Using Designed Experiments
R. Myers (1995)
10.1016/j.ejpb.2011.02.012
Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.
L. Souza (2011)
10.1016/J.JCONREL.2004.02.024
Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption.
C. Olbrich (2004)
10.1016/j.biomaterials.2007.12.037
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration.
W. D. de Jong (2008)
10.1088/0957-4484/24/41/415102
Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: ex vivo gut permeation studies.
Y. R. Neupane (2013)
10.3109/10611869609015973
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.
R. Mueller (1996)
10.5860/choice.44-5373
The Merck index : an encyclopedia of chemicals, drugs, and biologicals
S. Budavari (1983)
10.1007/BF02976689
Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats
H. Zhang (2003)
10.1016/j.ijbiomac.2014.05.066
Formulation of extended release cefpodoxime proxetil chitosan-alginate beads using quality by design approach.
A. Mujtaba (2014)
10.1016/J.CHERD.2013.05.032
Statistical optimization and characterization of pH-independent extended-release drug delivery of cefpodoxime proxetil using Box–Behnken design
A. Mujtaba (2014)
10.1016/j.ijpharm.2011.07.035
Lipid nanoparticles for brain targeting I. Formulation optimization.
P. Blasi (2011)
10.1080/1061186021000001832
Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate
C. Olbrich (2002)
10.1038/nrd2197
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
C. H. Porter (2007)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1248/BPB.30.1301
Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats.
Yulian Lin (2007)
10.1634/THEONCOLOGIST.9-5-482
FDA drug approval summaries: pemetrexed (Alimta).
M. Hazarika (2004)
10.33786/JCPR.2011.V01I02.012
Simvastatin loaded Solid lipid nanoparticles: Formulation optimization using Box Behnken design, characterization and in vitro evaluation
M. S. Gambhire (2011)
10.2147/IJN.S54529
Nanostructured lipid carrier-loaded hyaluronic acid microneedles for controlled dermal delivery of a lipophilic molecule
S. Lee (2014)



This paper is referenced by
10.2174/1567201817666200210120231
Development of pemetrexed diacid-loaded Gelatin-Cloisite 30B (MMT) nanocomposite for improved oral efficacy against cancer: Characterization, In-vitro and Ex-vivo Assessment.
Kriti Soni (2020)
10.1080/10826068.2019.1692220
Delivery of pemetrexed by magnetic nanoparticles: design, characterization, in vitro and in vivo assessment
Güliz Ak (2019)
10.1016/J.CEJ.2020.127016
Removal of Pemetrexed from aqueous phase using activated carbons in static mode
Bomin Fu (2021)
10.3390/pharmaceutics11070332
Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
Ruby Maharjan (2019)
10.1080/17425255.2019.1621289
Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs
S. Banerjee (2019)
10.2147/IJN.S167958
Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect
Rudra Pangeni (2018)
10.1016/j.jddst.2020.101899
Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: An insight into the in-vitro, ex-vivo, in-situ and in-vivo study models
Shashank Chaturvedi (2020)
10.1080/21691401.2017.1408124
Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments
Kriti Soni (2018)
10.1080/02652048.2019.1701114
Optimisation of ethosomal nanogel for topical nano-CUR and sulphoraphane delivery in effective skin cancer therapy
Kriti Soni (2019)
10.4018/978-1-5225-4781-5.CH005
Lipid Nanocarriers for Advanced Therapeutic Applications
V. Patravale (2018)
10.1186/s12951-019-0445-7
Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin–QDs nano-hybrids: covalent coupling and phospholipid complexation approaches
Dina G Zayed (2019)
Semantic Scholar Logo Some data provided by SemanticScholar